Newsfeeds - Spark Newswire

2 minute read

News

BIOCORP and Novo Nordisk Announced New Agreement on Mallya Smart Sensor

Today, 2:08 AM

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, announces the signature of a partnership agreement with Novo Nordisk for the commercialization of Mallya, initially in Japan.

NVO

1 minute read

Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants

By Vandana Singh

Today, 2:08 AM

Emergex Vaccines Holding Limited acquired the assets of Zosano Pharma Corporation. The sale was part of the customary proceedings after…

LLY

1 minute read

Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus’ Lead Drug Candidate

By Vandana Singh

Today, 2:08 AM

Biotechnology startup Ventus Therapeutics is licensing its lead research program, a drug candidate for inflammatory disorders, to Novo Nordisk A/S (NYSE:NVO) for…

NVO

1 minute read

Novo Nordisk Enters License Deal With Ventus Therapeutics To Develop Drugs To Treat Inflammatory Diseases

By Benzinga Newsdesk

Today, 2:08 AM

- Reuters

NVO

1 minute read

Ominous Death Cross Forms On Novo Nordisk’s Chart

By Benzinga Insights

Today, 2:08 AM

If history is any guide, there may be trouble ahead for shares of Novo Nordisk (NYSE:NVO). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

NVO

1 minute read

Novo Nordisk’s Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec

By Vandana Singh

Today, 2:08 AM

Novo Nordisk A/S (NYSE:NVO) presented new data from the phase 3a ONWARDS 2 trial of insulin icodec in type 2 diabetes…

NVO

1 minute read

Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels

By Vandana Singh

Today, 2:08 AM

Zealand Pharma A/S (NASDAQ:ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE:NVO) to commercialize Zegalogue (dasiglucagon) for…

NVO

1 minute read

Zealand Pharma Announced Global License and Development Agreement with Novo Nordisk for ZEGALOGUE; Zealand to Receive Upfront Payment of DKK 25M Plus Up to DKK 45M in Milestones

By Charles Gross

Today, 2:08 AM

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® (dasiglucagon) for injection.

NVO

1 minute read

Legal
News

Novo Nordisk To Pay $6.3M To Resolve False Claims Act Allegations

By Benzinga Newsdesk

Today, 2:08 AM

- Dow Jones Justice Dept.

NVO

3 minute read

Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk

By Benzinga Newsdesk

Today, 2:08 AM

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced

AEZS